views
Personalized cell therapy
involves using stem cells derived from a person's own body to develop
treatments specifically tailored to an individual's medical condition and
needs. The benefits of personalized cell therapy include its targeted
capability to repair or replace damaged cells and tissues. It also has the
potential to treat conditions considered incurable by other medical
interventions. Personalized cell therapies show promise in treating a wide
range of chronic and degenerative conditions. The global Personalized Cell
Therapy Market is estimated to be valued at US$ 5.56 Bn in 2023 and is expected to exhibit a CAGR of 13% over the forecast period
2023 to 2030, as highlighted in a new report published by Coherent Market
Insights.
Market key trends:
The increasing adoption of gene therapies is a major trend spurring growth in
the personalized cell therapy market. Gene therapy involves modifying genes or
introducing new ones to treat or prevent diseases. Several gene therapy
clinical trials have shown promising results in treating cancer, rare diseases,
and other severe conditions. Researchers are making significant advances in
developing safe and effective gene therapies for a wide range of medical
conditions. The development of innovative cell and gene therapies that can
precisely target the root cause of diseases is expected to transform medicine
and significantly boost the personalized cell therapy market over the forecast
period.
Segment
Analysis
The global Personalized Cell Therapy Market is broadly segmented based on
therapy type, therapeutic area, end-user, and region. By therapy type, the
market is divided into Stem Cell Therapy, Immunotherapy, CAR-T Cell Therapy and
others. Among these, the CAR-T Cell Therapy segment dominates owing to its
higher efficacy in treating cancer as compared to other available treatments
such as chemotherapy.
Key Takeaways
The Global
Personalized Cell Therapy Market Size is expected to witness high
growth during the forecast period of 2023 to 2030.
Regional analysis: North America is
currently the dominant region in the global personalized cell therapy market.
This is mainly due to the advanced healthcare infrastructure and increasing
R&D activities in the fields of cell and gene therapies. Additionally,
presence of key market players and favorable regulatory environment also
contribute to the high market share of North America.
Key players: Key players operating
in the Personalized Cell Therapy market are Continental AG, Valeo, Robert
Bosch, Denso Corporation, Magna International, Ficosa, ZF Friedrichshafen,
Gentex, Aptiv, Renesas Electronics. Continental AG dominates owing to its
strong product portfolio and global presence.
For
More Insights, Read: https://www.newswirestats.com/personalized-cell-therapy-market-demand-growth-and-regional-outlook-by-2030/
Comments
0 comment